Well Told Grants

Grants / Department of Health and Human Services / National Institutes of Health

RFA-HL-25-010: Phased Multi-Site Clinical Trial: Testing Prevention of Cardiovascular Disease in Young Adults With High Lifetime Risk Using Surrogate Outcomes - Clinical Coordinating Center (Collaborative UG3/UH3 Clinical Trial Required)

Closed Closed October 28, 2024 Opportunity RFA-HL-25-010

This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2024.

National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on October 28, 2024.

From the official notice on Grants.gov, last changed July 10, 2024. Checked November 7, 2026.

About this NIH notice

Projects funded under RFA-HL-25-010 were run by National Heart Lung and Blood Institute (NHLBI, 1 project). Contact the program officer at the institute that fits your project before you apply; the notice lists them.

Application due dates, page limits and budget limits are set in the notice. Read RFA-HL-25-010 in the NIH Guide.

Key dates

PostedJuly 10, 2024
DeadlineOctober 28, 2024
Archived by Grants.govDecember 3, 2024

Who can apply

This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.

All 15 applicant types the notice lists

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

More grants for nonprofits, colleges and universities, state and local governments, tribes, small businesses, businesses.

Is this a realistic fit?

What the grant funds

The goal of this funding opportunity for a Clinical Coordinating Center is to support a clinical trial which will test intervention(s) to reduce the progression of coronary atherosclerosis among young adults under the age of fifty years old who are at low or borderline 10-year risk ( 7.5%) for their first an atherosclerotic cardiovascular disease (ASCVD) event, yet at high lifetime risk of developing cardiovascular disease (CVD). This opportunity will support a two-phased primary prevention clinical trial that will first efficiently screen the appropriate population eligible for the intervention and second determine which intervention(s) are most efficacious at reducing the onset or slowing the progression of subclinical coronary atherosclerosis. It is expected that phase one will overlap with phase two. Trial participants who are identified as meeting the subclinical coronary atherosclerosis criteria for enrollment in the screening stage will be immediately enrolled in stage two even although stage one recruitment will continue until the trial is completely enrolled. It is expected that the trial will have three arms. One will be a control or comparison arm and the second and the third arm will test different interventions than the control arm. The control arm should be current guideline based behavioral interventions. One of the two non-control arms is expected to involvement pharmacological intervention(s) with definite evidence of efficacious for primary prevention in older high risk adults such as LDL- lowering therapy and the other arm may involve intervention(s) with less definite evidence of primary prevention efficacy in older adults The long range goal of this research strategy is to determine if earlier treatment prevents more CVD than current guideline recommended treatment. Applications for both a CCC and a DCC must be submitted on the same application due date for consideration by NHLBI.

Category: Health.

Funded under RFA-HL-25-010 so far

NIH funded 1 project under RFA-HL-25-010 in fiscal 2025 to 2026, at 1 institution. The median yearly award was $5.4 million.

Recently funded projects
ProjectInstitutionFiscal yearAward
1/2 PREEMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis UG3Duke University2026$6.8 million

From NIH RePORTER, which lists each project once per fiscal year it was funded. Amounts are the yearly award.

Who has won Cardiovascular Diseases Research grants before

From fiscal 2021 to 2025, Cardiovascular Diseases Research (93.837) awarded $15 billion across 11,798 grant awards, an average of $1.2 million per award.

Largest recipients, fiscal 2021 to 2025
RecipientStateAwardsAmount
The Trustees of the University of PennsylvaniaPennsylvania313$380 million
Brigham & Womens Hospital IncMassachusetts274$374 million
Regents of the University of MichiganMichigan277$355 million
The Trustees of Columbia University in the City of New YorkNew York207$335 million
University of Pittsburgh - of the Commonwealth System of Higher EducationPennsylvania295$320 million

Top states: California ($1.8 billion), Massachusetts ($1.5 billion), New York ($1.4 billion), Pennsylvania ($1.1 billion), Ohio ($749 million).

Applying now

This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.

The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.

Questions people ask

Is RFA-HL-25-010 still open?

No. It closed on October 28, 2024.

Who can apply for Phased Multi-Site Clinical Trial: Testing Prevention of Cardiovascular Disease in Young Adults With High Lifetime Risk Using Surrogate Outcomes - Clinical Coordinating Center (Collaborative UG3/UH3 Clinical Trial Required)?

National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.

What is the deadline for Phased Multi-Site Clinical Trial: Testing Prevention of Cardiovascular Disease in Young Adults With High Lifetime Risk Using Surrogate Outcomes - Clinical Coordinating Center (Collaborative UG3/UH3 Clinical Trial Required)?

Closed October 28, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.

Who has been funded under RFA-HL-25-010?

NIH RePORTER lists 1 project funded under RFA-HL-25-010 in fiscal 2025 to 2026, at 1 institution.

Who has won Cardiovascular Diseases Research grants before?

The largest recipients over five fiscal years were The Trustees of the University of Pennsylvania, Brigham & Womens Hospital Inc, Regents of the University of Michigan. The program made 11,798 awards worth $15 billion in that time.

Similar open grants